TABLE 1.
Patient characteristics and cumulative PPI use
| Total, n (%) | 14,147 | (100) |
|---|---|---|
| Age (years), median IQR | 63.3 | 52.1–73.6 |
| Age, group, n (%) | ||
| <50 | 3098 | (21.9) |
| 50–74 | 7974 | (56.4) |
| 75 | 3075 | (21.7) |
| Sex, n (%) | ||
| Women | 7691 | (54.4) |
| Men | 6456 | (45.6) |
| Ethnicity, n (%) | ||
| Jewish | 13,701 | (96.8) |
| Arab | 446 | (3.2) |
| Smoking status, n (%) | ||
| Current/past | 5019 | (35.5) |
| Helicobacter pylori status, n (%) | ||
| Negative | 10,055 | (71.1) |
| Positive | 4092 | (28.9) |
| Anti‐parietal cell antibodies, n (%) | ||
| Yes | 211 | (1.5) |
| PPI cumulative (DDD) a n (%) | ||
| Q1: 0–19 | 3566 | (25.2) |
| Q2: 20–89 | 3652 | (25.8) |
| Q3: 90–503 | 3410 | (24.1) |
| Q4: ≥504 | 3519 | (24.9) |
| Family history b n (%) | ||
| Yes | 120 | (0.8) |
| Charlson comorbidity index | ||
| None | 5298 | (37.4) |
| Mild | 5642 | (39.9) |
| Moderate | 2095 | (14.8) |
| Severe | 1110 | (7.8) |
| Missing | 2 | (0.0) |
| Body mass index quantiles (kg/m2) | ||
| 1st (<22.86) | 2802 | (19.7) |
| 2th (22.86–<25.35) | 2820 | (19.8) |
| 3rd (25.35–<27.68) | 2810 | (19.7) |
| 4th (27.68–30.83) | 2810 | (19.7) |
| 5th (≥30.83) | 2828 | (19.8) |
| Missing | 178 | (1.2) |
Abbreviations: DDD, drug daily dose; IQR, interquartile range; PPI, proton pump inhibitor.
a
Family history of malignancy of the gastrointestinal tract.
b
Q1–4: Quartiles of cumulative PPI dose (in DDD) within 10 years preceding index endoscopy.